Hydroxypropyl-β-cyclodextrin
Phase 2Small molecule
Hydroxypropyl-β-cyclodextrin is one of 34 small molecule programs targeting Niemann-Pick disease type C. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
430 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Levaquin
WWim Janssens
Preclinical
Hydroxypropyl-β-cyclodextrin
CCyclo Therapeutics, Inc.
Phase 2
Tylenol
KKenvue Brands
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Statins
SanofiPreclinical
Urokinase
Mmedac GmbH
Preclinical
Drug Therapy
MMassachusetts General Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Niemann-Pick disease type C1 trial
Ischemic stroke1 trial
The Androtriol Injection for the Treatment of Acute Ischemic Stroke
Not yet recruiting·—·Phase 2·NCT06679322·300 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCyclo Therapeutics, Inc.